|
|
|
|
|
A Look Ahead for 2013
|
|
|
| By
Angie Drakulich
|
|
|
|
From time to time, it's important to take stock of the industry from both a retrospective and prospective point of view.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Standards-Setting Activities on Impurities
|
|
|
| By
Maura Kibbey
,
Antonio Hernandez-Cardoso
,
Kahkashan Zaidi, PhD
|
|
|
|
USP's focus in 2013 involves standards relating to organic impurities, measurement of residual DNA and host-cell proteins in biotechnology products, and elemental impurities.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Report from Brazil
|
|
|
| By
Hellen Berger
|
|
|
|
The health ministry of Brazil recently signed an agreement to obtain its production technology to locally develop the antiretroviral drug atazavanir sulfate.
|
|
|
|
|
|
|
|
|
Strategies in API Scale Up
|
|
|
| By
Patricia Van Arnum
|
|
|
|
Process chemists employ a variety of approaches to improve yield, purity, and stereoselectivity.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EMA and FDA on Process Validation
|
|
|
|
Siegfried Schmitt, a principal consultant with PAREXEL, discusses the EMA's guideline on process validation and how it compares with FDA's process validaton guidance.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|